CN1104898C - 眼压降低剂 - Google Patents

眼压降低剂 Download PDF

Info

Publication number
CN1104898C
CN1104898C CN95193132A CN95193132A CN1104898C CN 1104898 C CN1104898 C CN 1104898C CN 95193132 A CN95193132 A CN 95193132A CN 95193132 A CN95193132 A CN 95193132A CN 1104898 C CN1104898 C CN 1104898C
Authority
CN
China
Prior art keywords
represent
group
general formula
methyl
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN95193132A
Other languages
English (en)
Chinese (zh)
Other versions
CN1148809A (zh
Inventor
横山富久
细川常通
柳泽宏明
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sankyo Co Ltd
Original Assignee
Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co Ltd filed Critical Sankyo Co Ltd
Publication of CN1148809A publication Critical patent/CN1148809A/zh
Application granted granted Critical
Publication of CN1104898C publication Critical patent/CN1104898C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Materials For Medical Uses (AREA)
CN95193132A 1994-03-16 1995-03-16 眼压降低剂 Expired - Fee Related CN1104898C (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP45404/1994 1994-03-16
JP4540494 1994-03-16
JP45404/94 1994-03-16

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNB021199396A Division CN1202819C (zh) 1994-03-16 2002-05-11 眼压降低剂

Publications (2)

Publication Number Publication Date
CN1148809A CN1148809A (zh) 1997-04-30
CN1104898C true CN1104898C (zh) 2003-04-09

Family

ID=12718322

Family Applications (2)

Application Number Title Priority Date Filing Date
CN95193132A Expired - Fee Related CN1104898C (zh) 1994-03-16 1995-03-16 眼压降低剂
CNB021199396A Expired - Fee Related CN1202819C (zh) 1994-03-16 2002-05-11 眼压降低剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNB021199396A Expired - Fee Related CN1202819C (zh) 1994-03-16 2002-05-11 眼压降低剂

Country Status (19)

Country Link
US (1) US5925664A (enExample)
EP (2) EP1110551B1 (enExample)
KR (1) KR100211446B1 (enExample)
CN (2) CN1104898C (enExample)
AT (2) ATE206050T1 (enExample)
AU (1) AU684916B2 (enExample)
CZ (1) CZ284395B6 (enExample)
DE (2) DE69533045T2 (enExample)
DK (2) DK0795326T3 (enExample)
ES (2) ES2221872T3 (enExample)
FI (2) FI114897B (enExample)
GR (1) GR3036989T3 (enExample)
HU (1) HUT74734A (enExample)
MX (1) MX9604109A (enExample)
NO (1) NO311068B1 (enExample)
NZ (1) NZ282485A (enExample)
PT (2) PT795326E (enExample)
RU (1) RU2123847C1 (enExample)
WO (1) WO1995024902A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL200009B1 (pl) * 1999-06-11 2008-11-28 Sankyo Co Kompozycja obniżająca ciśnienie wewnątrzgałkowe oraz zastosowanie antagonisty angiotensyny II do obniżania ciśnienia wewnątrzgałkowego
JP4000505B2 (ja) 1999-12-01 2007-10-31 第一三共株式会社 緑内障を治療するための併用剤
GR20000100281A (el) * 2000-08-17 2002-05-24 Ιωαννης Ματσουκας Ανταγωνιστες του υποδοχεα της αγγεοτενσινης ιι και συνθετικες μεθοδοι για την θεραπεια της υπερτασης και καρδιοαγγειακων ασθενειων
WO2002045748A1 (en) * 2000-12-05 2002-06-13 Sankyo Company, Limited Ocular tension-lowering compositions for topical administration
TWI349549B (en) * 2003-04-15 2011-10-01 Sankyo Co Medicament for treatment of intraocular angiopoietic disease

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2549049B1 (fr) * 1983-07-13 1986-06-20 Chauvin Blache Lab Nouvelles amidines, leur procede de preparation et leur application therapeutique
CA1334092C (en) * 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
US5138069A (en) * 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
JPS6323868A (ja) * 1986-07-11 1988-02-01 イー・アイ・デュポン・ドゥ・ヌムール・アンド・カンパニー アンギオテンシン２受容体遮断性イミダゾ−ル
US4820843A (en) * 1987-05-22 1989-04-11 E. I. Du Pont De Nemours And Company Tetrazole intermediates to antihypertensive compounds
US4880804A (en) * 1988-01-07 1989-11-14 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking benzimidazoles
CA1338238C (en) * 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
US4916129A (en) * 1989-01-19 1990-04-10 E. I. Du Pont De Nemours And Company Combination β-blocking/angiotensin II blocking antihypertensives
HU217958B (hu) * 1989-06-30 2000-05-28 E. I. Du Pont De Nemours And Co. Helyettesített imidazolszármazékok, ezeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
WO1991015206A1 (en) * 1990-04-05 1991-10-17 E.I. Du Pont De Nemours And Company Treatment of glaucoma and ocular hypertension with imidazole angiotensin-ii receptor antagonists
US5196444A (en) * 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US5126342A (en) * 1990-10-01 1992-06-30 Merck & Co., Inc. Imidazole angiotensin ii antagonists incorporating acidic functional groups
IS1756B (is) * 1991-02-21 2000-12-28 Sankyo Company Limited Hliðstæðuaðferð til framleiðslu 1-Biphenylmethylimidazole afleiða
US5616599A (en) * 1991-02-21 1997-04-01 Sankyo Company, Limited Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use
DE4132631A1 (de) * 1991-10-01 1993-04-08 Bayer Ag Imidazolyl-propensaeurederivate
US5219856A (en) * 1992-04-06 1993-06-15 E. I. Du Pont De Nemours And Company Angiotensin-II receptor blocking, heterocycle substituted imidazoles
DK0573218T3 (da) * 1992-06-02 2001-06-18 Sankyo Co 4-carboxyimidazolderivater som angiotensin-II antagonister og deres terapeutiske anvendelse
US5310929A (en) * 1992-08-06 1994-05-10 E. I. Du Pont De Nemours And Company Prodrugs of imidazole carboxylic acids as angiotensin II receptor antagonists
NO304429B1 (no) * 1992-12-17 1998-12-14 Sankyo Co Bifenylderivater, farmas°ytisk preparat og deres anvendelse for fremstilling av et medikament for behandling av hypertensjon og hjertesykdom
CZ154994A3 (en) * 1993-07-02 1995-09-13 Senju Pharma Co Visual hypotensive agent
WO1995021609A1 (en) * 1994-02-08 1995-08-17 Ciba-Geigy Ag Treatment of normotensive glaucoma with angiotensin ii antagonists

Also Published As

Publication number Publication date
AU684916B2 (en) 1998-01-08
ATE266402T1 (de) 2004-05-15
NO963854L (no) 1996-11-14
EP0795326A1 (en) 1997-09-17
WO1995024902A1 (en) 1995-09-21
CN1148809A (zh) 1997-04-30
FI114897B (fi) 2005-01-31
US5925664A (en) 1999-07-20
DK0795326T3 (da) 2001-11-26
EP0795326A4 (enExample) 1997-09-17
DK1110551T3 (da) 2004-06-07
NO963854D0 (no) 1996-09-13
MX9604109A (es) 1997-09-30
CN1387846A (zh) 2003-01-01
KR970701542A (ko) 1997-04-12
KR100211446B1 (ko) 1999-08-02
EP1110551B1 (en) 2004-05-12
NZ282485A (en) 1997-06-24
EP0795326B1 (en) 2001-09-26
PT1110551E (pt) 2004-07-30
CN1202819C (zh) 2005-05-25
ES2221872T3 (es) 2005-01-16
HUT74734A (en) 1997-02-28
FI20041236L (fi) 2004-09-24
ES2163501T3 (es) 2002-02-01
FI963645A7 (fi) 1996-11-14
CZ269496A3 (en) 1996-12-11
FI963645A0 (fi) 1996-09-16
RU2123847C1 (ru) 1998-12-27
CZ284395B6 (cs) 1998-11-11
EP1110551A3 (en) 2001-08-16
DE69533045T2 (de) 2005-01-27
NO311068B1 (no) 2001-10-08
HK1000551A1 (en) 2002-04-12
GR3036989T3 (en) 2002-01-31
DE69522955D1 (de) 2001-10-31
ATE206050T1 (de) 2001-10-15
DE69533045D1 (de) 2004-06-17
HU9602534D0 (en) 1996-11-28
FI115197B (fi) 2005-03-31
DE69522955T2 (de) 2002-05-29
EP1110551A2 (en) 2001-06-27
AU1960295A (en) 1995-10-03
PT795326E (pt) 2002-01-30

Similar Documents

Publication Publication Date Title
CN1170538C (zh) 供治疗关节病的法呢基(Farnesyl)蛋白质转移酶抑制剂
CN1075812C (zh) 吗啉速激肽受体拮抗剂的前药
CN1198807C (zh) 作为环加氧酶－2抑制剂的5－芳基－1h－1,2,4－三唑化合物及含有它们的药物组合物
CN1832742A (zh) 用于治疗心血管疾病的血管紧张素ii受体阻断剂氯沙坦、缬沙坦、坎地沙坦、替米沙坦、依普罗沙坦和奥美沙坦的硝基氧基衍生物
CN1069023A (zh) 用于治疗肥胖及相关状态的4-[2-(2-羟基-2-苯乙氨基)乙氧基]苯乙酸衍生物
CN1942186A (zh) 吡咯烷化合物
CN1358175A (zh) 嘧啶酮化合物
CN1279667A (zh) 4(3)取代－4(3)－氨基甲基－(硫代)吡喃(噻喃)或－哌啶衍生物(=加巴喷丁类似物)、其制备及其在治疗神经病方面的用途
CN1349524A (zh) 血管紧张肽原酶抑制剂
CN1131214C (zh) 作为兴奋性氨基酸拮抗剂的四氢喹啉衍生物
CN1160402A (zh) 用作pnp抑制剂的嘌呤和鸟嘌呤化合物
CN1906159A (zh) 前列腺素硝基氧衍生物
CN1151794C (zh) 治疗眼病的药用组合物
CN1173174A (zh) 取代的噁唑烷需钙蛋白酶和/或组织蛋白酶b抑制剂
CN1251098A (zh) 吡咯化合物,其制备及其用途
CN1671663A (zh) 截短侧耳素
CN1157375C (zh) 吲哚衍生物及其药物组合物
CN1062729A (zh) 可用作血管紧张肽转化酶抑制剂的含氨基和硝基的三环新化合物
CN1610683A (zh) 作为磷酸酶抑制剂的嘧啶并三嗪
CN1125575A (zh) 粘附受体拮抗剂
CN1284059A (zh) 联苯基脒衍生物
CN1675193A (zh) 1－甲基－2－(4－脒基苯基氨甲基)－苯并咪唑－5－基－羧酸－(n－2－吡啶基－n－2－羟基羰基乙基－酰胺的新颖前药，其制法及其作为药物制剂的用途
CN1074904A (zh) 苯并呋喃基-和噻吩基甲硫基-链烷羧酸衍生物
CN1104898C (zh) 眼压降低剂
CN1208333C (zh) 主要用于治疗骨质疏松的吲哚衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20030409

Termination date: 20100316